companies / phagos-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-06-12 json
| total_raised | 27,000,00027.0M | ○ |
|---|---|---|
| founded | null | |
| hq | Paris | |
| industry | unknown | |
| stage | series-a |
Phagos develops AI-designed bacteriophage therapies as a precise, sustainable alternative to antibiotics for bacterial infections in livestock. It serves chicken, cattle, swine, and shrimp farms worldwide. Its Alphagos platform pairs microbiology with AI to produce personalized phage treatments in about two months.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-10-01 | series-a | 27,000,00027.0M | null | ○ |
doubleclick floodlight, framer sites, google analytics, google tag manager, hsts, http/3, lucky orange, mysql, php, react 16.13.1, wordpress
| fact | status | src |
|---|---|---|
| Series A, $27.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |